Stockscreener 앱 받기
7.16
2.05%
-0.15
시간 외 거래:
7.17
0.010
+0.14%
전일 마감가:
$7.31
열려 있는:
$6.7
하루 거래량:
876.23K
Relative Volume:
0.95
시가총액:
$5.07M
수익:
-
순이익/손실:
$-12.88M
주가수익비율:
-0.2009
EPS:
-35.6417
순현금흐름:
$-8.79M
1주 성능:
+83.59%
1개월 성능:
+69.27%
6개월 성능:
-57.53%
1년 성능:
-58.13%
1일 변동 폭
$6.03
$7.18
1주일 범위
$3.75
$8.34
52주 변동 폭
$3.15
$85.80
Artelo Biosciences Inc Stock (ARTL) Company Profile
명칭
Artelo Biosciences Inc
전화
858-925-7049
주소
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
7.16 | 5.18M | 0 | -12.88M | -8.79M | -35.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-02-12 | 개시 | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences Enters Securities Purchase Agreements for Bridge Notes with Vanquish Funding Group and Boot Capital LLC - Minichart
Nano-cap Artelo Biosciences stock explodes — glaucoma study collaboration ignites rally - MSN
Artelo Biosciences Secures Bridge Financing Through Note Issuance - TipRanks
Artelo Biosciences Raises $310,000 in 12% Bridge Notes From Vanquish and Boot - TradingView
Artelo Biosciences (NASDAQ: ARTL) raises cash via 12% bridge notes - Stock Titan
Artelo Biosciences, Inc. 2025 Financial Results: Going Concern Risks, Capital Raises, and Significant Losses Detailed in Annual Report - Minichart
Small Cap Stocks To Watch NowMarch 18th - MarketBeat
Why Is Artelo Biosciences Stock Surging Today?Artelo Biosciences (NASDAQ:ARTL) - Benzinga
Artelo Biosciences completes 1-for-3 reverse stock split By Investing.com - Investing.com India
Artelo Biosciences (ARTL) Soars 40% After Securing Fully-Funded Glaucoma Trial Partnership - MEXC
Artelo Biosciences stock surges on glaucoma study agreement - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Artelo Biosciences moves into glaucoma research with fully funded clinical study - MSN
Artelo Biosciences (ARTL) Stock Jumps 40% on Surprise Glaucoma Study News - MEXC
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Benzinga
Artelo announces third-party fully funded clinical study agreement for ART27.13 - TipRanks
Artelo Biosciences’ Stock Increases with Positive R&D Updates - StocksToTrade
Artelo Biosciences jumps as it expands ART27.13 into glaucoma via fully funded clinical study - Quiver Quantitative
Artelo Biosciences (ARTL) Stock Rockets 40% Following Glaucoma Trial Partnership - parameter.io
Artelo Biosciences Shares Surge Amid Promising Research Updates - timothysykes.com
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
Morning Market Movers: ARTL, SWMR, OVID, HIT See Big Swings - RTTNews
Artelo Biosciences (ARTL) Explores New Glaucoma Treatment in Upc - GuruFocus
Artelo Biosciences, Inc.Common Stock (NQ: ARTL - The Chronicle-Journal
Artelo Biosciences and Belfast Health and Social Care Trust Enter Definitive Investigator-Initiated Study Agreement - marketscreener.com
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study - marketscreener.com
Glaucoma trial tests cannabinoid pill designed to protect vision - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why Is ARTL Stock Soaring Pre-Market Today? - Stocktwits
Clinical Collaboration and Funding Arrangement: Artelo Biosciences, Inc. (NASDAQ: ARTL) announces the signing of a third-party fully funded clinical research agreement to advance the evaluation of its candidate drug ART27.13 in glaucoma patients. - Bitget
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients - GlobeNewswire
Artelo Biosciences completes 1-for-3 reverse stock split - Investing.com
Artelo Biosciences Enacts Reverse Stock Split Amid Strain - TipRanks
Artelo Biosciences (NASDAQ: ARTL) posts loss and warns on going concern - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Artelo Biosciences launches underwritten public offering to raise capital - MSN
ARTELO B: Target Price Consensus and Analysts Recommendations | ARTL | US04301G6070 - marketscreener.com
Artelo Biosciences, Inc. announced that it has received $0.3503 million in funding from Vanquish Funding Group Inc., Boot Capital LLC - marketscreener.com
Artelo Biosciences announces 3-for-1 reverse stock split - Yahoo Finance
Artelo Biosciences implements 3-for-1 reverse stock split By Investing.com - Investing.com Australia
Aug PostEarnings: Is Artelo Biosciences Inc forming a bullish divergenceJuly 2025 Retail & Weekly High Momentum Picks - baoquankhu1.vn
Rate Hike: Is Artelo Biosciences Inc forming a bullish divergence2025 Big Picture & Fast Moving Trade Plans - baoquankhu1.vn
Artelo Biosciences announces reverse stock split - MSN
Artelo Biosciences implements 3-for-1 reverse stock split - Investing.com
Artelo Biosciences (Nasdaq: ARTL) plans 3-for-1 reverse stock split in March 2026 - Stock Titan
Artelo Biosciences Announces 3-for-1 Reverse Stock Split to Enhance Share Price and Marketability - Quiver Quantitative
Artelo Biosciences Announces Reverse Stock Split - TradingView
Artelo shrinks share count to 708K in 3-for-1 reverse split - Stock Titan
ARTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARTL SEC FilingsArtelo Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Artelo Biosciences Inc (ARTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):